Human papillomaviruses: Diseases, diagnosis, and a possible vaccine

Clinical Microbiology Newsletter

Volumn 27, Issue 18, 2005, Pages 139-145

  Greenblatt, Rebecca J ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VIRUS DNA; VIRUS VACCINE; WART VIRUS VACCINE;

CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CELL TRANSFORMATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; CONDYLOMA ACUMINATUM; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DNA DETERMINATION; DNA HYBRIDIZATION; ERYTHEMA; GENE EXPRESSION; GENE FUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INFECTION PREVENTION; INJECTION SITE REACTION; LABORATORY DIAGNOSIS; LABORATORY TEST; NONHUMAN; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; REVIEW; SEROTYPE; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VERRUCA PLANA JUVENILIS; VERRUCA PLANTARIS; VERRUCA VULGARIS; VIROGENESIS; VIROLOGY; VIRUS CARCINOGENESIS; VIRUS DETECTION; VIRUS GENE; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TRANSMISSION; WART VIRUS;

EID: 25644452649     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2005.09.001     Document Type: Article

References (38)

1. Major O. Human polyomavirus 4th ed. Knipe D.M. Howley P.M. Fields virology 2001 Lippincott Williams & Wilkins Philadelphia, PA
2. Khalili K. Human neurotropic polyomavirus, JCV, and its role in carcinogenesis Oncogene 22 2003 5181 5191
3. Hirsch H.H., Steiger J. Polyomavirus BK Lancet Infect. Dis. 3 2003 611 623
4. Howley P.M., Lowy D.R. Papillomaviruses and their replication 4th ed. Knipe D.M. Howley P.M. Fields virology 2001 Lippincott Williams & Wilkins Philadelphia, PA
5. Anhang R., Annekathryn G., Goldie S.J. HPV communication: review of existing research and recommendations for patient education CA Cancer J. Clin. 54 2004 248 259
6. Bode A.M., Dong Z. Post-translational modification of p53 in tumorigenesis Nat. Rev. Cancer 4 2004 793 805
7. Sanseverino F. Role of the retinoblastoma family in gynecological cancer Cancer Biol. Ther. 2 2003 636 641
8. Wentzensen N., Vinokurova S., Doeberitz M.V.K. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract Cancer Res. 64 2004 3878 3884
9. Schiller J.T., Lowy D.R. Papillomavirus-like particle vaccines J. Natl. Cancer Inst. Monogr. 28 2001 50 54
10. Suzich J.A. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas Proc. Natl. Acad. Sci. USA 92 1995 11553 11557
11. Breitburd F. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection J. Virol. 69 1995 3959 3963
12. Kirnbauer R. Virus-like particle of bovine papillomavirus type 4 in prophylactic and therapeutic immunization Virology 219 1996 37 44
13. Oh Y.K. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant Virology 328 2004 266 273
14. Ault K. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine Vaccine 22 2004 3004 3007
15. Fife K.H. Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women Vaccine 22 2004 2943 2952
16. Pinto L.A. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles J. Infect. Dis. 188 2003 327 338
17. Da Silva D.M., Schiller J.T., Kast W.M. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines Vaccine 21 2003 3219 3227
18. Park J.S. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems J. Med. Virol. 70 2003 633 641
19. Tobery T.W. Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques Vaccine 21 2003 1539 1547
20. Emeny R.T. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine J. Virol. 76 2002 7832 7842
21. + T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types J. Virol. 76 2002 7418 7429
22. Brown D.R. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer J. Infect. Dis. 184 2001 1183 1186
23. Evans T.G. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers J. Infect. Dis. 183 2001 1485 1493
24. Gerber S. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA J. Virol. 75 2001 4752 4760
25. Harro C.D. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine J. Natl. Cancer Inst. 93 2001 284 292
26. Pastrana D.V. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16 Virology 279 2001 361 369
27. Rose R.C. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies Vaccine 17 1999 2129 2135
28. Liu X.S. Mucosal immunization with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice Virology 252 1998 39 45
29. Balmelli C. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions J. Virol. 72 1998 8220 8229
30. Bryan J.T. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration J. Med. Virol. 53 1997 185 188
31. Lowe R.S. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast J. Infect. Dis. 176 1997 1141 1145
32. Nardelli-Haefliger D. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice Infect. Immun. 65 1997 3328 3336
33. Dupuy C. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles Microb. Pathog. 22 1997 219 225
34. Harper D.M. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 2004 1757 1765
35. Brown D.R. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine Vaccine 22 2004 2936 2942
36. Mao, C. Prophylactic human papillomavirus (HPV) 16 virus-like particle vaccine prevents HPV 16-related cervical intraepithelial neoplasia (CIN) grade 2 and 3. Presented to the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 29 - November 2, 2004, Washington, D.C.
37. Koutsky L.A. A controlled trial of a human papillomavirus type 16 vaccine N. Engl. J. Med. 347 2002 1645 1651
38. Warzecha H. Oral immunogenicity of human papillomavirus-like particles expressed in potato J. Virol. 77 2003 8702 8711